SAFETY DATA SHEETS

This SDS packet was issued with item:

078815132

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078923792

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

078815124



Printing date 07/23/2010 Reviewed on 07/23/2010

1 Identification of substance

- · Product details Product Name: Firocoxib 2% Injectable Solution for Horses.
- · Trade name: EQUIOXX Injectable Solution
- · Manufacturer/Supplier:

Merial Limited 3239 Satellite Blvd. Duluth, Ga. 30096-4640

1-888-MERIAL 1 (1-888-637-4251)

· Emergency information:

Spill Information:

CHEMTREC® 1-800-424-9300 CHEMTREC® International 1+703-527-3887 International calls 011+703-527-3887 Reverse charges.

2 Composition/Data on components

· Chemical characterization

· Components:					
189954-96-9	Firocoxib	R 52/53	2%		
	Non hazardous substance		98%		

· Additional information:

Merial regards the identity of the individual components of this formulation to be proprietary information which is being withheld in accordance with the Trade Secret provisions of 29 CFR 1910.1200. Certain of the ingredients included may be classified as health hazards, the effects of which would be presumed to be mitigated in the mixture. The excipients in Equioxx are generally recognized as safe, and/or are used in various food, pharmaceutical and/or cosmetic products or applications. Thus they are considered safe for all relevant worst-case user exposure scenarios.

3 Hazards identification

· Hazard description:

CAUTION! Exposure may cause eye or skin or respiratory irritation. May be harmful if swallowed in large quantities. Keep container tightly closed when not in use. Do not eat, drink, or smoke while handling this product. Wash thoroughly, as appropriate, after handling.

· Classification system:

The classification was made according to the latest editions of international substances lists, and from company and regulatory data.

· NFPA ratings (scale 0 - 4)



Health = 1 Fire = 0Reactivity = 0

USA ·

Printing date 07/23/2010 Reviewed on 07/23/2010

Trade name: EQUIOXX Injectable Solution

· HMIS-ratings (scale 0 - 4)



4 First aid measures

- · After inhalation: If lungs are irritated or breathing is difficult, move patient to fresh air and contact a physician.
- · After skin contact:

In case of contact, immediately wash skin with plenty of water. Remove contaminated clothing and shoes and launder before reuse. If skin irritation develops and persists or recurs, contact a physician.

· After eye contact:

In case of contact, flush eyes with plenty of water for at least 15 minutes. Call a physician if irritation persists.

· After swallowing:

If swallowed and patient is conscious, induce vomiting immediately as directed by a physician, preventing aspiration. Never give anything by mouth to an unconscious person. Get medical attention immediately, and show label of compound.

- · After self injection
- · Information for doctor. Use symptomatic treatment. There is no specific antidote to this compound.

5 Fire fighting measures

· Suitable extinguishing agents:

Carbon dioxide or dry chemical extinguishers. Large fires with "alcohol"-type foam extinguishers. Use extinguishing media appropriate for surrounding materials.

- $\cdot \textit{Special hazards caused by the material, its products of combustion or resulting gases:} \\$
- None known. When heated to decomposition, it may produce acrid smoke and irritating fumes.
- · Protective equipment: Self-contained breathing apparatus and full protective equipment.

6 Accidental release measures

- · Person-related safety precautions: Not required.
- · Measures for environmental protection: No special measures required.
- · Measures for cleaning/collecting:

For small spills, using protective equipment as prescribed in Section 8, carefully collect all spilled product in absorbent material and place in sealed container for disposal in accordance with Section 13.

· Additional information:

For transportation-related and large spills call CHEMTREC at 1-800-424-9300. If outside the U.S.A., call CHEMTREC collect at +1-703-527-3887.

7 Handling and storage

- · Handling:
- · Information for safe handling:

No smoking, eating, or drinking while using this product. Keep container tightly closed when not in use. Provide for adequate local ventilation.

· Information about protection against explosions and fires: No special measures required.

IISA -

Printing date 07/23/2010 Reviewed on 07/23/2010

Trade name: EQUIOXX Injectable Solution

- · Storage:
- Requirements to be met by storerooms and receptacles: Store only in the original container.
- · Information about storage in one common storage facility: Not required.
- Further information about storage conditions: Store in a cool, dry, well ventilated place.
- · Recommended storage temperature: 20-25°C

8 Exposure controls and personal protection

- · Additional information about design of technical systems: Use good general local exhaust ventilation.
- · Components with limit values that require monitoring at the workplace:

The product does not contain any relevant quantities of materials with critical values that have to be monitored at the workplace.

- · Personal protective equipment:
- · General protective and hygienic measures:

Wash hands before breaks and at the end of work.

Avoid contact with the eyes and skin.

Do not eat, drink, smoke or inhale.

Do not store food in the working area.

· Breathing equipment:

Wear mask with organic vapor cartridge when cleaning up spills. For normal working conditions, ensure adequate exhaust ventilation to ensure vapors do not accumulate.

· Protection of hands:

Wear butyl rubber or other impervious gloves when using this product to prevent skin contact. Wash thoroughly after handling.

· Eye protection:

Wear chemical splash goggles when cleaning spilled product or if the potential for eye contact exists. Wear safety glasses with side shields for normal handling.

· Body protection: Impervious protective clothing

9 Physical and chemical properties

· *Viscosity at 25°C (77°F):*

· General Information		
Form:	Liquid	
Color:	Clear, pale yellow	
Odor:	No odor	
· Change in condition	n ling range: Undetermined.	
· Flash point:	Not applicable.	

40 Cp

Boiling point/Boiling range: Undetermined.				
· Flash point:	Not applicable.			
· Auto igniting:	Product is not self-igniting.			
· Danger of explosion:	Product does not present an explosion hazard.			
· Specific gravity:	Not determined.			
· Solubility in / Miscibility with Water:	Not miscible or difficult to mix.			

USA -

Printing date 07/23/2010 Reviewed on 07/23/2010

Trade name: EQUIOXX Injectable Solution

• Organic solvents: 98 %

10 Stability and reactivity

- · Thermal decomposition / conditions to be avoided: Avoid exposure to heat, sparks, or flame.
- · Materials to be avoided: May react with strong oxidizers or reducers.
- · Dangerous reactions No dangerous reactions known.
- · Dangerous products of decomposition:

Thermal decomposition may release oxides of carbon, small molecular weight hydrocarbons and uncharacterized products.

11 Toxicological information

- · Acute toxicity:
- · LD/LC50 values that are relevant for classification:

Acute oral LD50 > 2000 mg/kg

Acute dermal LD50 >2000 mg/kg

- · Primary irritant effect:
- · on the skin: May irritate the skin.
- · on the eye: May cause irritation.
- · Sensitization: No sensitizing effects known.
- · Other information (about experimental toxicology):

Toxicologic properties of this product have not been fully evaluated. Based on individual component data from animal studies, over-exposure may result in vomiting, lethargy, drowsiness, eye redness and localized pain, difficulty breathing, salivation, and diarrhea.

· Additional toxicological information:

CARCINOGENICITY:

None of the components of this formulation are carcinogenic.

MUTAGENICITY:

None of the components of this formulation are mutagenic.

REPRODUCTIVE EFFECTS:

Firocoxib is a potential reproductive toxin.

TERATOGENICITY / DEVELOPMENTAL EFFECTS:

Firocoxib is a potential teratogen or developmental toxin.

INTERACTIONS WITH OTHER CHEMICALS WHICH ENHANCE TOXICITY:

There are no data on potential interactions between this mixture and other chemicals.

12 Ecological information

- · Ecotoxological effects:
- · Aquatic toxicity:

Firocoxib: Daphnia test, 48 hr: EC50 > saturation limit (32.5 mg/l)

Algae test, 72 hr: IC50 = 11 mg/l

USA

Printing date 07/23/2010 Reviewed on 07/23/2010

Trade name: EQUIOXX Injectable Solution

13 Disposal considerations

- · Product:
- · Recommendation:

Must not be disposed of together with household garbage. Do not allow product to reach sewage system.

- · Uncleaned packagings:
- · Recommendation: Disposal must be made according to official regulations.

14 Transport information

- · DOT regulations:
- · Hazard class: None
- · Land transport ADR/RID (cross-border):
- · ADR/RID class: None
- · Maritime transport IMDG:
- · IMDG Class: None
- · Marine pollutant: No
- · Air transport ICAO-TI and IATA-DGR:
- · ICAO/IATA Class: None

15 Regulations

- \cdot SARA
- · Section 355 (extremely hazardous substances):

None of the ingredients are listed.

· Section 313 (Specific toxic chemical listings):

None of the ingredients are listed.

· TSCA (Toxic Substances Control Act):

None of the ingredients are listed.

- · CA Proposition 65
- · Chemicals known to cause cancer:

None of the ingredients are listed.

· Chemicals known to cause reproductive toxicity for females:

None of the ingredients is listed.

· Chemicals known to cause reproductive toxicity for males:

None of the ingredients is listed.

· Chemicals known to cause developmental toxicity:

None of the ingredients is listed.

- · Carcinogenesis potential categories
- · EPA (Environmental Protection Agency)

None of the ingredients is listed.

· IARC (International Agency for Research on Cancer)

None of the ingredients is listed.

USA

Printing date 07/23/2010 Reviewed on 07/23/2010

Trade name: EQUIOXX Injectable Solution

· NTP (National Toxicology Program)

None of the ingredients is listed.

· TLV (Threshold Limit Value established by ACGIH)

None of the ingredients is listed.

· MAK (German Maximum Workplace Concentration)

None of the ingredients is listed.

· NIOSH-Ca (National Institute for Occupational Safety and Health)

None of the ingredients is listed.

· OSHA-Ca (Occupational Safety & Health Administration)

None of the ingredients is listed.

· Product related hazard informations:

Observe the general safety regulations when handling chemicals.

The product is not subject to identification regulations according to directives on hazardous materials. Like other medicinal products that inhibit COX-2, pregnant women or women attempting to conceive should avoid contact with, or wear disposable gloves, when administering the product.

16 Other information

This information is based on our present knowledge. However, this shall not constitute a guarantee for any specific product features and shall not establish a legally valid contractual relationship.

· Contact: MSDS Coordinator, msds@merial.com

USA